Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.

Nana Kragh, Anna Tytula,Michał Pochopien,Samuel Aballéa,Mondher Toumi,Zalmai Hakimi,Jameel Nazir,Linda Bystrická,Francis Fatoye

European journal of haematology（2023）

引用 1|浏览7

暂无评分

摘要

rFVIIIFc has proven efficacy and is cost-effective compared with emicizumab, providing clinicians with a viable treatment option to improve the health outcomes for adults and adolescents with haemophilia A in the UK.

查看译文

关键词

cost-effectiveness analysis,emicizumab,haemophilia A,prophylaxis,recombinant factor VIII Fc

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要